Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis

Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta‐Analyses Supporting AASLD Guidelines

(2020) John M. Vierling et al.   HEPATOLOGY

Second-line and Third-line therapy for Autoimmune Hepatitis A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group

(2020) Ansgar W. Lohse et al.   JOURNAL OF HEPATOLOGY

A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis

(2019) Mohamad Hanouneh et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis

(2019) Priscila Santiago et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the study of liver diseases

(2019) Cara L. Mack et al.   HEPATOLOGY

Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis

(2018) Cumali Efe et al.   DIGESTIVE DISEASES AND SCIENCES

A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment

(2018) Michele De Lemos-Bonotto et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Diagnosis and Management of Pediatric Autoimmune Liver Disease

(2018) Giorgina Mieli-Vergani et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

EASL Clinical Practice Guidelines: Autoimmune hepatitis

(2015)   JOURNAL OF HEPATOLOGY